Unexpectedly, our data revealed that stathmin does not play any role in tumor onset in mice, reinforcing the hypothesis that stathmin could be used as marker of tumor aggressiveness and as therapeutic target in metastatic patients. Here, STMN1 is linked to neoplasm.